FENDRR

Summary

FENDRR (FOXF1 adjacent non-coding developmental regulatory RNA, HGNC:43894) is a long non-coding RNA gene on chromosome 16q24.1.

This gene produces a spliced long non-coding RNA transcribed bidirectionally with FOXF1 on the opposite strand. A similar gene in mouse is essential for normal development of the heart and body wall. The encoded transcript is thought to act by binding to polycomb repressive complex 2 (PRC2) and/or TrxG/MLL complexes to promote the methylation of the promoters of target genes, thus reducing their expression. It has been suggested that this transcript may play a role in the progression of gastric cancer. Alternatively spliced transcript variants have been identified.

Source: NCBI Gene 400550 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43894
Approved symbol	FENDRR
Name	FOXF1 adjacent non-coding developmental regulatory RNA
Location	16q24.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	lincFOXF1, onco-lncRNA-21
Ensembl gene	ENSG00000268388
Ensembl biotype	lncRNA
OMIM	614975
Entrez	400550
RNAcentral	URS0000759D4A — lncRNA, 3099 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 17 lncRNA

ENST00000593604, ENST00000594398, ENST00000595886, ENST00000597578, ENST00000598996, ENST00000599749, ENST00000600553, ENST00000659025, ENST00000659486, ENST00000659545, ENST00000662100, ENST00000667117, ENST00000669311, ENST00000671115, ENST00000749540, ENST00000749541, ENST00000749542

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000593604 — 2 exons

Exon	Start	End
ENSE00003019555	86487718	86491004
ENSE00003093618	86508655	86508877

Expression profiles

Bgee: expression breadth ubiquitous, 188 present calls, max score 96.85.

FANTOM5 (CAGE): breadth broad, TPM avg 3.2864 / max 347.1118, expressed in 362 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158444	2.7603	357
158440	0.2311	59
158442	0.1438	60
158445	0.1237	76
158443	0.0275	15

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lung	UBERON:0002167	96.85	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.52	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.31	gold quality
lower esophagus	UBERON:0013473	95.27	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.53	gold quality
mucosa of stomach	UBERON:0001199	94.49	gold quality
colonic epithelium	UBERON:0000397	94.24	gold quality
upper lobe of left lung	UBERON:0008952	91.25	gold quality
transverse colon	UBERON:0001157	90.51	gold quality
rectum	UBERON:0001052	90.22	gold quality
urinary bladder	UBERON:0001255	89.95	gold quality
upper lobe of lung	UBERON:0008948	89.66	gold quality
colon	UBERON:0001155	89.42	gold quality
large intestine	UBERON:0000059	88.98	gold quality
gall bladder	UBERON:0002110	88.76	gold quality
intestine	UBERON:0000160	88.45	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.74	gold quality
body of stomach	UBERON:0001161	87.67	gold quality
stomach	UBERON:0000945	87.27	gold quality
fundus of stomach	UBERON:0001160	87.09	gold quality
mucosa of transverse colon	UBERON:0004991	86.72	gold quality
small intestine	UBERON:0002108	86.62	gold quality
vermiform appendix	UBERON:0001154	85.96	gold quality
esophagus	UBERON:0001043	85.72	gold quality
lung	UBERON:0002048	85.30	gold quality
caecum	UBERON:0001153	84.79	gold quality
prostate gland	UBERON:0002367	84.14	gold quality
lower esophagus mucosa	UBERON:0035834	82.87	gold quality
epithelial cell of pancreas	CL:0000083	81.37	silver quality
smooth muscle tissue	UBERON:0001135	79.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.74

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 26)

• FENDRR plays an important role in the progression and metastasis of gastric cancer. (PMID:25167886)
• Results suggest that long noncoding RNA FOXF1-AS1 might regulate epithelial-mesenchymal transition (EMT), stemness and metastasis of non-small cell lung cancer (NSCLC) cells via EZH2, indicating it as a therapeutic target for future treatment of NSCLC. (PMID:27577075)
• These findings suggested the CNVR_3425.1 of FENDRR to be a possibly predictive biomarker for the risk of lung cancer and chronic obstructive pulmonary disease (PMID:29293945)
• FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. (PMID:29465000)
• lncRNAs MHRT, FENDRR and CARMEN show distinct expression profiles in hypertensive patients (PMID:29917257)
• Over-expression of FENDRR inhibited the malignant phenotypes of non-small cell lung carcinoma cells by binding competitively to miR-761. (PMID:30556873)
• FENDRR attenuates NSCLC cell stemness through inhibiting the HuR/MDR1 axis (PMID:30981768)
• FENDRR silences survivin via SETDB1-mediated H3K9 methylation, thereby represses cholangiocarcinoma cell proliferation, migration and invasion. (PMID:30983519)
• Screening of significant biomarkers related with prognosis of liver cancer by lncRNA-associated ceRNAs analysis. (PMID:31502679)
• FENDRR reduces tumor invasiveness in prostate cancer PC-3 cells by targeting CSNK1E. (PMID:31539119)
• long noncoding RNA FENDRR suppressed the progression of non-small cell lung cancer via binding to miR-761 and regulating TIMP2 expression. (PMID:31545237)
• LncRNA FENDRR Upregulation Promotes Hepatic Carcinoma Cells Apoptosis by Targeting miR-362-5p Via NPR3 and p38-MAPK Pathway. (PMID:32251605)
• LncRNA Fendrr inhibits hypoxia/reoxygenation-induced cardiomyocyte apoptosis by downregulating p53 expression. (PMID:32537758)
• Integrated Analysis of lncRNAs and mRNAs Identifies a Potential Driver lncRNA FENDRR in Lung Cancer in Xuanwei, China. (PMID:32590916)
• Long non-coding RNA FENDRR regulates IFNgamma-induced M1 phenotype in macrophages. (PMID:32792604)
• Decreased long non-coding RNA lincFOXF1 indicates poor progression and promotes cell migration and metastasis in osteosarcoma. (PMID:32945076)
• FENDRR Sponges miR-424-5p to Inhibit Cell Proliferation, Migration and Invasion in Colorectal Cancer. (PMID:33356998)
• N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. (PMID:33692441)
• Lung-specific distant enhancer cis regulates expression of FOXF1 and lncRNA FENDRR. (PMID:33739555)
• FENDRR: A pivotal, cancer-related, long non-coding RNA. (PMID:33761608)
• Long non-coding RNA FENDRR regulates proliferation, apoptosis and migration in high-glucose-induced human retinal endothelial cells via targeting miR-384/RHOA axis. (PMID:33764715)
• LncRNA FENDRR Expression Correlates with Tumor Immunogenicity. (PMID:34200642)
• Long Noncoding RNA FENDRR Inhibits Lung Fibroblast Proliferation via a Reduction of beta-Catenin. (PMID:34445242)
• Long non-coding RNA FENDRR inhibits the stemenss of colorectal cancer cells through directly binding to Sox2 RNA. (PMID:34697986)
• An integrated analysis of the competing endogenous RNA network associated of prognosis of stage I lung adenocarcinoma. (PMID:35183135)
• The Emerging Role of LncRNA FENDRR in Multiple Cancers: A Review. (PMID:35579154)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.